Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
Pauline CorbauxGilles FreyerOlivier GlehenBenoit YouNaoual BakrinAudrey GelotDavid DaydeChristophe SajousMax PiffouxJulien PéronGaelle LescuyerLéa PayenVahan KepenekianPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
This is the first study demonstrating the feasibility of IP nivolumab in patients with relapsed advanced ovarian cancer; further investigation at 3 mg/kg is warranted.